This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Free Reports

MannKind Fails Twitter Like It Does Afrezza

Someone needs to send MannKind executives a primer on the uses of Twitter hashtags.

Gilead: Most Valuable Biotech Asset in Market Is Our Own Stock

Foster City, Calif.-based biotech giant Gilead announced a new $12 billion share repurchase plan on Tuesday night in conjunction with fourth-quarter earnings.

Axovant Sinks on Pfizer Alzheimer's Drug Blowup

The disclosure that Pfizer shelved an Alzheimer's drug because of disappointing efficacy is driving down the market value of Axovant Sciences, which is developing a similar drug.

Exelixis Kidney Cancer Survival Benefit Doesn't Address Competitive Question

Exelixis didn't provide specifics about the duration of Cometriq's survival benefit, so it's not known if the new data will help the company compete any better against Bristol-Myers Squibb.

Biotech String: Assessing the January Damage, Gilead's Bottoming P/E, Sarepta Panel Date?

Biotech news and observations to start the week.

Merck Takes on Gilead With Sharply Lower Hepatitis C Drug Price

The list price for Merck's newly approved hepatitis C drug is lower than competing therapies from Gilead Sciences and Abbvie, which means a new price war could be heating up.

Celldex Nears Pivotal Decision Point for Brain Tumor Therapy

Celldex will announce the outcome of an interim analysis for a pivotal study of its brain tumor therapy Rintega within weeks.

Assume No More Biogen Drug Price Hikes? Not So Fast

The controversy over drug pricing factored into Biogen's revenue guidance for 2016.

Juno, Kite Valuations at Risk From Simpler T-Cell Cancer Therapy

Juno and Kite Pharma are under pressure Tuesday after U.S. government researchers published a study showing an off-the-shelf, engineered T-cell therapy could induce remissions in patients with blood cancers.

Biotech String: Editas IPO Terms, Rooting for Shkreli in DC

Biotech news and observations to start the week.

Page 1 of 350
< Previous
Top Rated Stocks Top Rated Funds Top Rated ETFs